Key facts
- Kindling Bio’s last known valuation is $1.6M (Oct 2025).
- It has raised $260K; the latest was Seed Round ($260K) in Oct 2025.
- Notable investors include Deep Science Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Kindling Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kindling Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kindling Bio
Developer of an advancing pediatric-led next-generation cancer gene therapies designed to reprogram tumor biology. The company features the ability to harness the power of the immune system to fight a wide range of tumors, enabling clinicians to advance precision therapy for children with cancer.
- Sector
- Healthcare
- HQ
- Ingatestone, United Kingdom
- Founded
- 2025
- Employees
- 3
- Website
- kindlingbio.com/
- Ownership
- Privately Held (backing)
Kindling Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kindling Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kindling Bio in its N-PORT filings yet. We sweep new filings monthly.